

IMPACT FACTOR 5.2





an Open Access Journal by MDPI

Artificial Intelligence in Cancer Screening

Guest Editors:

Prof. Dr. Mario Mascalchi

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50121 Florence, Italy

Prof. Dr. Stefano Diciotti

Department of Electrical, Electronic, and Information Engineering "Guglielmo Marconi" - DEI, University of Bologna, Bologna, Italy

Deadline for manuscript submissions:

31 October 2024

Message from the Guest Editors

Artificial intelligence (AI) is a powerful class of methods for decision support, having rapidly evolved over recent years. Several approaches have been developed to analyze the increasingly extensive and variably complex datasets often publicly available. With enthusiasm, AI is beginning to be applied to several facets of screening intervention, from the risk stratification of subjects to be invited, to the reading of radiological, optical, and histo-cytopathological images, and integration with stool, serum, and fluid biomarkers to ultimately promote and reinforce the implementation of screening in public health services, thanks to an improved cost/benefit ratio.

In this Special Issue of *Cancers*, we offer an overview of the current and potential applications of AI to the screening interventions considering, on the one hand, the AI methodological and technical developments and, on the other hand, the applications to specific screening contexts.

- artificial intelligence
- biomarkers
- breast cancer
- cancer screening
- cervical cancer
- colorectal cancer
- deep learning
- lung cancer
- machine learning
- risk stratification













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us